Now it’s time to turn to something completely different.
Here we look at hepatocellular carcinoma (HCC), including Blueprint Medicines FGFR4 molecule, BLU–554.
We first covered Blueprint back in February this year with a particular focus on GIST. Quite a bit has changed since then, so it’s a good time for an update, especially in HCC now that they have data in Madrid.
In the context of the HCC landscape, what’s changing in this niche, what should our expectations be, and how is this market evolving since our last update?